Health Canada maintains that the benefits of the Oxford-AstraZeneca COVID-19 vaccine continue to outweigh the possible risks, after the first blood clot-related fatality was reported on Tuesday.In a statement released late Tuesday, the Public Health Agency of Canada (PHAC) said it received a report from Quebec of a person who died after experiencing “Thrombosis with thrombocytopenia with unusual blood clots with low platelets following vaccination with the AstraZeneca COVID-19 vaccine.” Quebec reports first death due to blood clot after AstraZeneca vaccine The agency said it extends its “sincere condolences to the individual’s family and friends for the loss of their loved one.”Health officials in Quebec on Tuesday confirmed the victim.